Dementia or mild cognitive impairment due to Alzheimer?s disease affect millions of Americans. Clinically, it is characterized by general cognitive decline and prominent memory impairments. However, one of the first functions to be affected in Alzheimer?s disease is the sense of smell. In fact, olfactory dysfunction often precedes the onset of other cognitive and memory impairments. In the brain, olfactory information is processed along the lateral olfactory tract (LOT), a white-matter bundle that connects the olfactory bulb to cortical areas including the piriform cortex and entorhinal cortex. Paralleling olfactory perceptual deficits in Alzheimer?s disease, post- mortem studies show that neurodegeneration is first observable in olfactory brain regions such as the olfactory bulb and entorhinal cortex. Based on this evidence, we hypothesize that olfactory impairments and cognitive decline in early-stage Alzheimer?s disease are both related to neurodegeneration in the LOT. The integrity of white-matter pathways in the human brain can be measured in vivo using diffusion-weighted magnetic resonance imaging (dMRI). However, dMRI in olfactory structures is technically challenging because of prominent signal dropout and image deformations in these areas. To overcome these challenges, a major goal of the parent project (R01DC015426) is to develop a novel dMRI protocol and analysis pipeline to image the human LOT. Our preliminary results of aim 3 of the parent project demonstrate that we are now able to image the human LOT with unprecedented quality. The goal of this application for administrative supplement is to use our new imaging technologies to directly test our hypothesis regarding LOT neurodegeneration in Alzheimer?s disease. We propose to measure the integrity of the LOT in participants with early-stage Alzheimer?s disease and age- matched cognitively normal control participants. We will compare LOT integrity between groups, and test whether these measures correlate with olfactory perceptual deficits and cognitive decline. The proposed work will characterize LOT neurodegeneration in Alzheimer?s disease using in vivo imaging techniques, and build the basis for novel biomarkers for Alzheimer?s disease that are sensitive to cognitive decline. Such biomarkers will be non-invasive and thus can be used to identify at-risk populations before cognitive decline occurs. In addition, the results from this project may inform mechanistic models of Alzheimer?s disease and aid the development of new treatments that target neurodegeneration in specific brain areas.

Public Health Relevance

The proposed research will combine cutting-edge neuroimaging and olfactory psychophysics to identify the neural principles of olfactory reward processing in the human brain, and whether they are compromised in Alzheimer?s diseases. The findings from this research may be important for clarifying the effects of odors on human decision-making. Moreover, they may have particular clinical relevance for neurodegenerative diseases, where anosmia and changes in olfactory hedonic processing may underlie symptoms of altered food preferences, hyperorality, and consumption of non-foods.

Agency
National Institute of Health (NIH)
Institute
National Institute on Deafness and Other Communication Disorders (NIDCD)
Type
Research Project (R01)
Project #
3R01DC015426-04S1
Application #
10097477
Study Section
Program Officer
Sullivan, Susan L
Project Start
2020-09-01
Project End
2021-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
4
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Neurology
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611